These firms further contend that the costs of pharmaceutical Raamp;D have been escalating rapidly, effective patent lives have been declining, ... In view of these trends, they contend that the rate of Raamp;D investment will be insufficient for the rapid transition of scientific advances. ... Some research-intensive firms argue that the present trends have driven many companies away from pharmaceutical Raamp;D andanbsp;...
|Title||:||Patent-term extension and the pharmaceutical industry.|
|Publisher||:||DIANE Publishing -|